About Us

CuraVac is presently preparing a phase 2 efficacy clinical trial with a more potent formulation of the MG Therapeutic Vaccine : CV-MG02.

CuraVac is a clinical-stage biotech company developing the medical and commercial potential of a revolutionary technique for the production of specific Therapeutic Vaccines for the treatment of autoimmune diseases.

The company was founded by a Belgian medical doctor, Dr. St├ęphane Huberty, who at the time, suffered from myasthenia gravis. The original discoverer of the Vaccine production technique, Professor J. Edwin Blalock soon joined CuraVac as a consultant.

In this video you will find a presentation of CuraVac, who we are and what we believe in, as well as an explanation of the principle behind our revolutionary Therapeutic Vaccine for Myasthenia Gravis and other autoimmune diseases.

This vaccine is the first in a series. It will be tested on humans suffering from myasthenia gravis (MG). While not a widely known orphan disease, MG affects more than one in five thousand and its pathology is clearly understood, making it an excellent development model.

Further, CuraVac’s Therapeutic Vaccines will be developed for the treatment of other autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis and systemic lupus erythematosus.

In total, autoimmune diseases afflict more than five percent of western population.

  • In 2002, the company was created and acquired the complementary peptide patent. The company raised funds and got organized as a management company in the center of an expertise and competence network of collaborations and sub-contracting companies.
  • In 2006, the key article showing that the MG vaccine works not only in the lab on rat models but also on naturally occurring myasthenia gravis in pet dogs is published and the MG vaccine patent is filed.
  • In 2009, the human formulation of the MG vaccine is manufactured following GLP and GMP guidelines.
    The myasthenia gravis Therapeutic Vaccine, our first vaccine, was granted Orphan Drug Designation in Europe by a team of independent experts of the 27 European member states.
The Myasterix Team

Our Story

Foundation

CuraVac was founded in 2002 by Dr. St├ęphane Huberty, a Belgian medical doctor who suffered from Myasthenia Gravis. Soon after, the company acquired the complementary peptide patent, raised funds and got organized as a management company at the center of a network of collaborations and sub-contracting companies. The original discoverer of the vaccine production technique, Professor J. Edwin Blalock also joined CuraVac as a consultant.

Present day

Following a Clinical Trial Authorization received in November 2015, 24 patients received three injections of the MG therapeutic vaccine in a phase 1B clinical trial that took place at the Antwerp University hospital (UZA) in Belgium. The preliminary results were communicated in May 2017 at the 13th International Conference on Myasthenia Gravis and Related Disorders at the New York Academy of Science. The final results of phase 1B, communicated in June 2018, demonstrated an excellent safety profile and called for a phase 2 efficacy clinical trial. CuraVac is presently preparing a phase 2 efficacy clinical trial with a more potent formulation of the MG Therapeutic Vaccine: CV-MG02.